menu
    • menu
    [{"orgOrder":0,"company":"Hasten Biopharmaceutic","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibiotic","year":"2023","type":"Acquisition","leadProduct":"Ceftriaxone","moa":"||Cell wall peptidoglycan synthesis","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Hasten Biopharmaceutic","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Hasten Biopharmaceutic \/ Hasten Biopharmaceutic","highestDevelopmentStatusID":"15","companyTruncated":"Hasten Biopharmaceutic \/ Hasten Biopharmaceutic"},{"orgOrder":0,"company":"Hasten Biopharmaceutic","sponsor":"CBC Group","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Financing","leadProduct":"Azilsartan","moa":"||Angiotensin II receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Hasten Biopharmaceutic","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Hasten Biopharmaceutic \/ CBC Group","highestDevelopmentStatusID":"15","companyTruncated":"Hasten Biopharmaceutic \/ CBC Group"},{"orgOrder":0,"company":"Hasten Biopharmaceutic","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Azilsartan","moa":"||Angiotensin II receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Hasten Biopharmaceutic","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Hasten Biopharmaceutic \/ Hasten Biopharmaceutic","highestDevelopmentStatusID":"15","companyTruncated":"Hasten Biopharmaceutic \/ Hasten Biopharmaceutic"},{"orgOrder":0,"company":"Hasten Biopharmaceutic","sponsor":"Celltrion","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Azilsartan","moa":"||Angiotensin II receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Hasten Biopharmaceutic","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Hasten Biopharmaceutic \/ Hasten Biopharmaceutic","highestDevelopmentStatusID":"15","companyTruncated":"Hasten Biopharmaceutic \/ Hasten Biopharmaceutic"},{"orgOrder":0,"company":"Hasten Biopharmaceutic","sponsor":"Celltrion","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Azilsartan","moa":"||Angiotensin II receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Hasten Biopharmaceutic","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Hasten Biopharmaceutic \/ Hasten Biopharmaceutic","highestDevelopmentStatusID":"15","companyTruncated":"Hasten Biopharmaceutic \/ Hasten Biopharmaceutic"},{"orgOrder":0,"company":"Hasten Biopharmaceutic","sponsor":"LIB Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||PCSK9","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Hasten Biopharmaceutic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Hasten Biopharmaceutic \/ Hasten Biopharmaceutic","highestDevelopmentStatusID":"10","companyTruncated":"Hasten Biopharmaceutic \/ Hasten Biopharmaceutic"},{"orgOrder":0,"company":"Hasten Biopharmaceutic","sponsor":"LIB Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2023","type":"Licensing Agreement","leadProduct":"Inapplicable","moa":"||PCSK9","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Hasten Biopharmaceutic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Hasten Biopharmaceutic \/ Hasten Biopharmaceutic","highestDevelopmentStatusID":"10","companyTruncated":"Hasten Biopharmaceutic \/ Hasten Biopharmaceutic"},{"orgOrder":0,"company":"Hasten Biopharmaceutic","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Divestment","leadProduct":"Urapidil Hydrochloride","moa":"||AR-alpha1","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Hasten Biopharmaceutic","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Hasten Biopharmaceutic \/ Hasten Biopharmaceutic","highestDevelopmentStatusID":"15","companyTruncated":"Hasten Biopharmaceutic \/ Hasten Biopharmaceutic"},{"orgOrder":0,"company":"Hasten Biopharmaceutic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||Subtilisin\/kexin type 9","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Hasten Biopharmaceutic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hasten Biopharmaceutic \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Hasten Biopharmaceutic \/ Inapplicable"},{"orgOrder":0,"company":"Hasten Biopharmaceutic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"HST101","moa":"||PCSK9","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Hasten Biopharmaceutic","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hasten Biopharmaceutic \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Hasten Biopharmaceutic \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Hasten Biopharmaceutic

    Menu

    Hasten Biopharmaceutic

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Hasten Biopharmaceutic

                            China arrow
                            EPSC
                            Not Confirmed

                            Hasten Biopharmaceutic

                            China arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lerodalcibep,Inapplicable

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study on Efficacy and Safety of HST101 in Chinese Patients with Hypercholesterolemia

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            August 23, 2024

                            Lead Product(s) : Lerodalcibep,Inapplicable

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Hasten Biopharmaceutic

                            China arrow
                            EPSC
                            Not Confirmed

                            Hasten Biopharmaceutic

                            China arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HST101,Inapplicable

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study on Evaluating the Safety of HST101 in Healthy Chinese Participants

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            July 16, 2024

                            Lead Product(s) : HST101,Inapplicable

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Hasten Biopharmaceutic

                            China arrow
                            EPSC
                            Not Confirmed

                            Hasten Biopharmaceutic

                            China arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Azilsartan,Inapplicable

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved FDF

                            Recipient : Celltrion

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Chinese startup Hasten Biopharma buys 14 products from Korean firm Celltrion

                            Details : Through this acquisition, Hasten leverages commercial rights to treatments for various chronic disease, which include the approved product Edarbi (azilsartan medoxomil), indicated for hypertension.

                            Product Name : Edarbi

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            June 28, 2024

                            Lead Product(s) : Azilsartan,Inapplicable

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved FDF

                            Recipient : Celltrion

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Hasten Biopharmaceutic

                            China arrow
                            EPSC
                            Not Confirmed

                            Hasten Biopharmaceutic

                            China arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lerodalcibep,Inapplicable

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Recipient : LIB Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            LIB Therapeutics and Hasten Announce Acceptance of Lerodalcibep Clinical Trial Application

                            Details : LIB003 (lerodalcibep) is a potential best in class, novel, small binding protein, third-generation PCSK9 inhibitor, which is being evaluated for the treatment and prevention of cardiovascular disease.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            March 19, 2024

                            Lead Product(s) : Lerodalcibep,Inapplicable

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Recipient : LIB Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Hasten Biopharmaceutic

                            China arrow
                            EPSC
                            Not Confirmed

                            Hasten Biopharmaceutic

                            China arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Azilsartan,Inapplicable

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved FDF

                            Recipient : Celltrion

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Chinese startup Hasten Biopharma buys 14 products from Korean firm Celltrion

                            Details : Through the acquisition, Hasten will own the Marketing Authorisation Holder rights of products in 8 countries, which includes Edarbi (azilsartan medoxomil) indicated for the treatment of hypertension.

                            Product Name : Edarbi

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            February 07, 2024

                            Lead Product(s) : Azilsartan,Inapplicable

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved FDF

                            Recipient : Celltrion

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Hasten Biopharmaceutic

                            China arrow
                            EPSC
                            Not Confirmed

                            Hasten Biopharmaceutic

                            China arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lerodalcibep,Inapplicable

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Recipient : LIB Therapeutics

                            Deal Size : $325.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            LIB Therapeutics and Hasten Biopharmaceutical Company Announce $325 Million Strategic Collaboration to Develop...

                            Details : Under the terms of the agreement, LIB has granted Hasten the exclusive rights to develop and commercialize LIB003 (lerodalcibep), a next-generation, PCSK9 inhibitor, for patients at very high and high-risk of cardiovascular disease, in Greater China.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : $20.0 million

                            December 09, 2023

                            Lead Product(s) : Lerodalcibep,Inapplicable

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Recipient : LIB Therapeutics

                            Deal Size : $325.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Hasten Biopharmaceutic

                            China arrow
                            EPSC
                            Not Confirmed

                            Hasten Biopharmaceutic

                            China arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Azilsartan,Inapplicable

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved FDF

                            Sponsor : CBC Group

                            Deal Size : $315.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            CBC Group and Mubadala Co-Lead US$315 Million Fundraising Round for Hasten Biopharma

                            Details : The proceeds will fund the future acquisitions and business development of five cardiovascular and metabolic products, including Ebrantil®, Edarbi®, Blopress®, Basen®, and Actos®. Edarbi (azilsartan medoxomil) is an angiotensin II receptor blocker, ...

                            Product Name : Edarbi

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            April 20, 2023

                            Lead Product(s) : Azilsartan,Inapplicable

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : CBC Group

                            Deal Size : $315.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Hasten Biopharmaceutic

                            China arrow
                            EPSC
                            Not Confirmed

                            Hasten Biopharmaceutic

                            China arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ceftriaxone,Inapplicable

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Recipient : F. Hoffmann-La Roche

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Hasten Acquires Commercial Rights In China For Roche’s Antibiotic Rocephin®

                            Details : Under the agreement, Hasten acquired Roche's China mainland rights for Rocephin® (ceftriaxone sodium), a long-acting, broad spectrum cephalosporin antibiotic, including the product's marketing authorization and certain intellectual property, including t...

                            Product Name : Rocephin

                            Product Type : Antibiotic

                            Upfront Cash : Undisclosed

                            April 05, 2023

                            Lead Product(s) : Ceftriaxone,Inapplicable

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Recipient : F. Hoffmann-La Roche

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Hasten Biopharmaceutic

                            China arrow
                            EPSC
                            Not Confirmed

                            Hasten Biopharmaceutic

                            China arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Azilsartan,Inapplicable

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved FDF

                            Recipient : Takeda Pharmaceutical

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            CBC Group-backed Hasten Biopharma Successfully Completes Acquisition Of Five Cardiovascular And Metabolism Dru...

                            Details : Under the acquisition agreement, Hasten Biopharma will have exclusive rights to five drugs including, Ebrantil (urapidil), Edarbi (azilsartan medoxomil), Blopress (candesartan cilexetil), Basen®, and Actos® in mainland China.

                            Product Name : Edarbi

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            March 31, 2022

                            Lead Product(s) : Azilsartan,Inapplicable

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved FDF

                            Recipient : Takeda Pharmaceutical

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Hasten Biopharmaceutic

                            China arrow
                            EPSC
                            Not Confirmed

                            Hasten Biopharmaceutic

                            China arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Urapidil Hydrochloride,Inapplicable

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved FDF

                            Recipient : Takeda Pharmaceutical

                            Deal Size : $322.0 million

                            Deal Type : Divestment

                            DEALS_DEV arrow-down

                            Takeda Furthers Innovation-Focused Strategy in China with Sale of Select Non-Core Assets to Hasten for $322 mi...

                            Details : The portfolio to be divested to Hasten includes cardiovascular and metabolism products sold in mainland China which includes Ebrantil®.

                            Product Name : Ebrantil

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            December 21, 2020

                            Lead Product(s) : Urapidil Hydrochloride,Inapplicable

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved FDF

                            Recipient : Takeda Pharmaceutical

                            Deal Size : $322.0 million

                            Deal Type : Divestment

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth